Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597202 | 0.83 | NOS3 (0.35) | ALDH1A1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1912301 | 0.81 | LOX (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL335739 | 0.81 | RECQL (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1145964 | 0.80 | ALDH1A1 (0.38) | ALDH1A1KDM4ECYP3A4CYP2C19HIF1A | |
| Hydrochloric Acid SCHEMBL14801170 | 0.79 | LOX (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13859499 | 0.78 | CYP1A2 (0.33) | ALDH1A1KDM4ECYP3A4CYP2C19CHRNB2 | |
| SCHEMBL17229261 | 0.78 | ALDH1A1 (0.34) | ALDH1A1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13859197 | 0.78 | KDM4E (0.35) | ALDH1A1KDM4ECHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1141323 | 0.77 | ALDH1A1 (0.42) | ALDH1A1CHRNB2CHRNA4NPSR1 | |
| SCHEMBL30833526 | 0.77 | ALDH1A1 (0.42) | ALDH1A1CHRNB2CHRNA4NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621230-B | Nitrogen-containing heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-114621230-A | Nitrogen-containing heterocyclic compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-9238646-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | NOVARTIS AG (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9238646-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | NOVARTIS AG (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-5428032-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1995-06-27 | — | — | US | disclosed |
| EP-0629191-A1 | PROCESS FOR PREPARING 2-HALO-5-HALOMETHYLPYRIDINES | REILLY INDUSTRIES, INC. (US) | 1994-12-21 | — | — | EP | disclosed |
| US-5298507-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1994-03-29 | — | — | US | disclosed |
| WO-1993018004-A1 | PROCESS FOR PREPARING 2-HALO-5-HALOMETHYLPYRIDINES | REILLY INDUSTRIES, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| US-5229519-A | Process for preparing 2-halo-5-halomethylpyridines | REILLY INDUSTRIES, INC. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5204360-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5001138-A | Insecticides | NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) | 1991-03-19 | — | — | US | disclosed |
| US-4845106-A | INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4742060-A | 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0192060-A1 | Heterocyclic compounds | NIHON BAYER AGROCHEM K.K. (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | ALDH1A1 232/4885KDM4E 2412/4885CYP3A4 543/4885 |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | WNT1, CTNNB1, CTNNA1 | ALDH1A1 232/4885KDM4E 2412/4885CYP3A4 543/4885 |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | ALDH1A1 232/4885KDM4E 2412/4885CYP3A4 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.